Phase 1 Study of CB-839, a First-in-Class, Glutaminase Inhibitor in Patients with Multiple Myeloma and Lymphoma von Vogl, Dan T., Younes, Anas, Stewart, Keith, Orford, Keith William, Bennett, Mark, Siegel, David, Berdeja, Jesus G.

Volltext

Phase 1 Study of CB-839, a First-in-Class, Orally Administered Small Molecule Inhibitor of Glutaminase in Patients with Relapsed/Refractory Leukemia von Wang, Eunice S., Frankfurt, Olga, Orford, Keith William, Bennett, Mark, Flinn, Ian W., Maris, Michael, Konopleva, Marina

Volltext

STAPLED PEPTIDES AND METHODS THEREOF von HUROV, Jonathan Barry, ORFORD, Keith William, HAN, Xinwei, YU, Lihua, MARTINOT, Theodore Anael, SI, Yaguang

Volltext bestellen

Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in... von Bendell, Johanna C., Atreya, Chloe Evelyn, André, Thierry, Tabernero, Josep, Gordon, Michael S., Bernards, Rene, Van Cutsem, Eric, Tejpar, Sabine, Sidhu, Roger, Go, William Y., Allred, Alicia, Motwani, Monica, Suttle, Benjamin B., Wu, Yuehui, Hoos, Axel, Orford, Keith W., Corcoran, Ryan Bruce, Schellens, Jan HM

Volltext